ConjuChem Biotechnologies Inc. announced today that the USPTO has issued an Action Closing Prosecution in the inter partes reexamination of Patent No. 6,924,264. The patent, entitled "Modified Exendins and Exendin Agonists," was issued in August 2005 and is assigned to Amylin Pharmaceuticals, Inc. The Action Closing Prosecution rejected all the claims for obviousness and/or lack of novelty. The inter partes reexamination in the USPTO does not involve any of ConjuChem's patents.
The details can be read here.
No comments:
Post a Comment